Lenangio 10, Lenalidomide, AntiCancer Drugs, Online Pharmacy, ZarvyPharm

Lenangio 10

★★★★★

(0)

Generic For	REVLIMID
Active Ingredient	LENALIDOMIDE
Strength	10MG
Manufacturer	DR REDDYS LABORATORIES

Pack Size	Price Per Unit	Unit Price	Best Coupon Price MAX DISCOUNT
★ Best Value 3 BOXES - 30 CAPSULES	$ 3.73	$ 112.00	$ 95.20 Apply ZARVY26 (-15%) You save $ 16.80
★ Best Value 6 BOXES - 60 CAPSULES	$ 4.07	$ 244.00	$ 207.40 Apply ZARVY26 (-15%) You save $ 36.60
★ Best Value 9 BOXES - 90 CAPSULES	$ 3.91	$ 352.00	$ 299.20 Apply ZARVY26 (-15%) You save $ 52.80

Pack Size

Price Per Unit

Unit Price

QTY

CART

Best Coupon Price
MAX DISCOUNT

3 BOXES - 30 CAPSULES

$ 3.73

$ 112.00

$ 95.20

Apply ZARVY26 (-15%)

You save $ 16.80

6 BOXES - 60 CAPSULES

$ 4.07

$ 244.00

$ 207.40

Apply ZARVY26 (-15%)

You save $ 36.60

★ Best Value 9 BOXES - 90 CAPSULES

$ 3.91

$ 352.00

$ 299.20

Apply ZARVY26 (-15%)

You save $ 52.80

Product Description

Lenangio 10 is an oral anticancer capsule formulated with 10mg of lenalidomide, a potent second-generation immunomodulatory drug derived from thalidomide. It exerts multiple therapeutic actions including direct anti-proliferative effects, inhibition of tumor angiogenesis, immune system modulation, and induction of apoptosis in malignant cells. Lenangio 10 is particularly effective in treating hematologic malignancies such as multiple myeloma, myelodysplastic syndromes, and various lymphomas, playing a critical role in both initial therapy and long-term disease control.

Indications & Uses

AntiCancerDrugs > Multiple Myeloma
Lenangio 10 is widely utilized in the frontline and relapsed treatment of multiple myeloma, often in combination with dexamethasone or proteasome inhibitors like bortezomib. It enhances T-cell and NK-cell cytotoxicity, inhibits cytokine production, and disrupts microenvironmental support of myeloma cells. It is also used in maintenance therapy following autologous stem cell transplant to prolong remission and improve overall survival.
Myelodysplastic Syndrome (MDS)
In patients with low or intermediate-1 risk MDS with 5q deletion, Lenangio 10 has been shown to significantly reduce the need for red blood cell transfusions and improve bone marrow function. It is the first FDA-approved agent targeting this specific cytogenetic abnormality, making it a critical treatment option for transfusion-dependent anemia.
Lymphoma
Lenangio 10 is indicated in relapsed or refractory mantle cell lymphoma (MCL), especially in patients who have failed prior treatments such as bortezomib. It is also used off-label in follicular lymphoma (FL) and marginal zone lymphoma (MZL), typically in combination with rituximab, offering an alternative therapeutic approach in indolent B-cell malignancies.
Off-label in CLL and Other Lymphoproliferative Disorders
Emerging studies suggest the utility of lenalidomide in chronic lymphocytic leukemia (CLL) and other hematologic cancers due to its ability to modulate immune responses and disrupt leukemic cell survival pathways.

Benefits & Effectiveness

Inhibits Ikaros and Aiolos transcription factors via cereblon pathway
Enhances natural killer and T-cell function
Suppresses inflammatory cytokines and disrupts stromal support
Improves erythropoiesis in MDS
Delays relapse in lymphoproliferative disorders

Directions for Use

Multiple Myeloma (MM)

In combination with dexamethasone: 25 mg orally once daily on Days 1–21 of a 28-day cycle
Continue until disease progression or unacceptable toxicity
Maintenance therapy post-autologous HSCT: Start with 10 mg once daily on Days 1–28 of 28-day cycles for 3 cycles

If tolerated, increase to 15 mg once daily and continue long-term

Notes: For non-transplant candidates, lenalidomide is continued until disease progression

For transplant candidates, stem cell mobilization is recommended within 4 cycles
Blood counts must meet recovery thresholds before initiating maintenance
Myelodysplastic Syndromes (MDS)
10 mg orally once daily
Dosage may be adjusted based on hematologic and cytogenetic response
Designed for use in patients with transfusion-dependent anemia and 5q deletion
Lymphoma
Follicular Lymphoma (FL) / Marginal Zone Lymphoma (MZL): 20 mg orally once daily on Days 1–21 of a 28-day cycle for up to 12 cycles

Use in combination with rituximab
Mantle Cell Lymphoma (MCL): 25 mg orally once daily on Days 1–21 of a 28-day cycle
Continue until progression or unacceptable toxicity

Storage

Store at room temperature below 25°C. Keep the capsules in their original blister packaging to protect from light and moisture. Ensure safe storage away from children and pregnant women due to high teratogenic risk. Dispose of unused medication in accordance with local pharmaceutical waste protocols.

Possible Side Effects

- Common: Fatigue, neutropenia, rash, diarrhea, constipation - Serious: Venous thromboembolism, febrile neutropenia, secondary primary malignancies - Others: Thyroid dysfunction, hepatotoxicity, increased infection risk

FAQs

Yes, it is often used for maintenance post-transplant or as continuous therapy in non-transplant settings.

No. Lenangio 10 is highly teratogenic and strictly contraindicated in pregnancy. Women of childbearing potential must use two forms of contraception.

Frequent monitoring is required, especially of CBC, liver enzymes, renal function, and thyroid profile to prevent complications.

Yes, it is commonly combined with dexamethasone, bortezomib, or rituximab depending on the cancer type and treatment phase.

Take the missed dose as soon as you remember unless it's close to the next dose. Do not double the dose to catch up.

Ratings & Reviews

Reviewed by 0 Users

0/5

★★★★★

5★

4★